人脑胶质瘤组织中MTERF3的表达及其预后意义  

Expression of MTERF3 in human brain glioma tissues and its relationship with the prognosis

作　　者：林亚茹 刘如爱 自加吉 普元倩 陈莹 戴莉萍 余敏[4] 熊伟 LIN Yaru;LIU Ru'ai;ZI Jiaji;PU Yuanqian;CHEN Ying;DAI Liping;YU Min;XIONG Wei(College of Basic Medical Sciences,Dali University,Yunnan Dali 671000,China;Key Laboratory of Clinical Biochemistry in Yunnan Provincial Universities,Yunnan Dali 671000,China;Department of Pathology,Dali Bai Autonomous Prefecture People's Hospital,Yunnan Dali 671000,China;College of Life Sciences,Yunnan University,Yunnan Kunming 650091,China.)

机构地区：[1]大理大学基础医学院,云南大理671000 [2]云南省高校临床生物化学检验重点实验室,云南大理671000 [3]大理白族自治州第一人民医院病理科,云南大理671000 [4]云南大学生命科学学院,云南昆明650091

出　　处：《现代肿瘤医学》2024年第3期443-450,共8页Journal of Modern Oncology

基　　金：国家自然科学基金项目(编号:32160167,82160516);云南省应用基础研究专项面上项目(编号:202201AT070004,202301AT070023);云南省昆虫生物医药研发重点实验室开放课题(编号:AG202203,AP2022006)。

摘　　要：目的:研究线粒体转录终止因子3(mitochondrial transcription termination factor 3,MTERF3)基因在人脑胶质瘤组织中的表达情况,并探讨MTERF3基因表达量与患者临床病理特征及预后的相关性。方法:采用RT-PCR、Western blot和免疫组化SP法检测28例人脑胶质瘤组织及10例非肿瘤脑组织中MTERF3mRNA和蛋白质的表达水平。利用R语言软件从癌症基因组图谱(TCGA)数据库下载522例胶质瘤组织及10例非肿瘤脑组织中MTERF3基因mRNA表达量、临床病理参数及预后资料,探讨人脑胶质瘤患者临床病理参数与MTERF3 mRNA表达量之间的联系。采用Kaplan-Meier法分析MTERF3 mRNA表达量与人脑胶质瘤患者累积生存时间(overall survival, OS)和无疾病进展生存时间(disease-free survival, DFS)的关系。采用Cox回归多因素分析探讨影响脑胶质瘤患者预后的因素。采用cBioportal分析脑胶质瘤中MTERF3基因与脑胶质瘤分子标志物基因mRNA表达量的相关性。结果:免疫组织化学结果显示,MTERF3蛋白主要表达于细胞质,人脑胶质瘤中的阳性表达率为64.29%,且在高级别的脑胶质瘤中MTERF3阳性表达率(81.25%)高于其低级别的阳性表达率(41.67%)。RT-PCR和Western blot结果显示,与非瘤脑组织相比,MTERF3 mRNA和蛋白质在不同级别人脑胶质瘤中的表达水平均显著增高,差异有统计学意义(P<0.05)。TCGA数据集分析表明,在脑胶质瘤组织中MTERF3 mRNA的表达水平明显高于非瘤脑组织(P<0.01),且MTERF3 mRNA表达量与病理类型、患者年龄、WHO分级有关(均P<0.05),而与性别、发病部位、样本类型无关。Kaplan-Meier分析发现,MTERF3高表达患者的OS和DFS均显著低于MTERF3低表达的患者(Log-rank P<0.01)。Cox多因素分析表明,患者年龄和病理类型均是导致脑胶质瘤患者预后不良的独立影响因素(均P<0.05)。脑胶质瘤中MTERF3基因与IDH1、 TP53、MKI67基因mRNA的表达量呈显著正相关性(均P<0.01,r>0),而与PTEN、RBFOX3�Objective:To investigate the expression of mitochondrial transcription termination factor 3(MTERF3)gene in human glioma tissues,and to analyze its relationship with clinicopathological characteristics and prognosis.Methods:RT-PCR,Western blot,immunohistochemistry were performed to analyze the mRNA and protein expression levels of MTERF3 in 28 human brain glioma tissues and 10 non-cancerous brain tissues.MTERF3 mRNA expression,clinicopathological parameters and prognosis of 522 brain glioma tissues and 10 non-cancerous brain tissues were downloaded from TCGA database by R language software.The relationship between the expression of MTERF3 mRNA and clinicopathological characteristics was analyzed.Kaplan-Meier method was used to analyze the relationship between MTERF3 mRNA expression and overall survival(OS)and disease-free survival(DFS)in human brain glioma.Cox regression model was performed for the multivariate analysis of the factors affected the prognosis of brain glioma.cBioportal was used to analyze the correlation between MTERF3 gene expression level and biomarker genes expression level in brain gliomas.Results:The immunohistochemistry results showed that MTERF3 protein was located in cytoplasma,and the positive expression rate of MTERF3 protein in brain glioma tissues was 64.29%.The positive expression rate of MTERF3 protein in high grade glioma tissues(81.25%)was higher than that in low grade glioma tissues(41.67%).The expression level of MTERF3 mRNA and protein in brain glioma tissues was significantly higher than that in non-cancerous brain tissues by RT-PCR and Western blot(P<0.05).The analysis of TCGA dataset showed that the expression level of MTERF3 mRNA in glioma tissues was significantly higher than that in non-cancerous brain tissues(P<0.01),and the expression level of MTERF3 mRNA was related to pathological type,age and WHO grade(all of which were P<0.05),but not gender,incidence site and sample type.Kaplan-Meier analysis showed that the OS and DFS of patients with high MTERF3 expression were sign

关 键 词：线粒体转录终止因子3 脑胶质瘤 免疫组化 TCGA数据集 预后意义 

分 类 号：R739.41[医药卫生—肿瘤]